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Biotherapeutic products (BTPs) are the fastest growing medicines in the pharmaceutical market. Despite
their clinical success, the immunogenicity of BTPs continues to be a major concern. Assessment of
immunogenicity as well as appropriate interpretation of immunogenicity data is therefore, of critical
importance for deﬁning safety proﬁle of these products for the purpose of their licensure and use. In the
past decade, much progress has been made towards how immunogenicity should be studied. This article
reﬂects the content of the brief presentation on principles of methods used for immunogenicity
assessment and their merits and limitations given at the ﬁrst World Health Organization (WHO)
implementation workshop on rDNA derived biotherapeutic products held in the Republic of Korea in
May 2014 to support the case studies on immunogenicity presented and discussed during the workshop.
The purpose of this article is to provide an overview of the methods used for assessing immunogenicity
of biotherapeutic products (BTPs) and the most important considerations in interpreting results in the
context of regulatory overview of these products.
Crown Copyright © 2015 Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Since approval of the ﬁrst recombinant biotherapeutic product
(BTP), insulin in 1982, several BTPs have been successfully approved
for treatment of various indications. Despite their success, BTPs
when administered to patients can elicit immune responses that
may directly impact product safety and efﬁcacy. For example, an-
tibodies that develop in response to a BTP may alter the product's
pharmacokinetic proﬁle, diminish its pharmacodynamic effect and
compromise clinical efﬁcacy [1e6]. In some instances, they can
cause undesirable effect(s), such as hypersensitivity reactions or
severe adverse events (for example, profound anaemia) that can
even be fatal [7e11]. Well-known examples are thrombocytopenia
in patients treated with thrombopoietin (TPO) and pure red cell
aplasia in chronic renal disease patients treated with Eprex, an
approved erythropoietin (EPO) product, following induction of
neutralizing antibodies which cross-reacted with the functionally
non-redundant endogenous EPO [7,8]. Since immunogenicity hasadhwa).
vier Ltd on behalf of The Internation
es/by-nc-nd/4.0/).been reported with various products including monoclonal anti-
bodies [9,11e14], immunogenicity continues to receive signiﬁcant
attention from regulatory bodies, industry and clinicians.
Immunogenicity assessment is one of the regulatory
requirements for BTP approval which includes the review of
immunogenicity studies and the interpretation of the results. As
stated in WHO Guidelines on BTPs [15], immunogenicity should be
investigated in the target population since animal testing and
in vitro models cannot predict immune response in humans. In
addition, immunogenicity has a role in demonstrating product
comparability following manufacturing changes and similarity in
the context of biosimilar development [15,16]. Even minor changes
can potentially affect the bioactivity, efﬁcacy or safety including
immunogenicity of a BTP. Consequently, guidance has been pro-
vided by regulatory agencies e European Medicines Agency (EMA)
and Food and Drug Administration (FDA), United States Pharma-
copoiea and white papers published by industry with the expec-
tation that these guidance documents will facilitate
immunogenicity assessment [17e21]. For a biosimilar, demonstra-
tion of similarity in terms of immunogenicity of a biosimilar in a
head-to-head comparison to the reference product is a critical
parameter for deﬁning its safety proﬁle [16,17].al Alliance for Biological Standardization. This is an open access article under the CC
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disease related inﬂuence immunogenicity [22,23]. The structural
characteristics of the therapeutic product for example, native
amino acid sequence or variant, any chemically modiﬁed forms,
presence of aggregates, process related impurities for example,
host cell proteins, formulation changes, primary packaging -
container, the functional properties of the protein, the patient's
genetic predisposition and immune status, the type of disease(s),
concomitant medication, frequency and route of administration,
single/multiple use and previous exposure are some of the
contributory risk factors for immunogenicity (Table 1). While
glycosylation does not appear to play a major role, non-human or
non-mammalian glycosylations within the product due to the
expression system used can induce immune responses. An example
is cetuximabwhich contained a terminal galactose-a-1, 3-galactose
because of the expression system used and caused anaphylaxis in
patients with pre-existing cross-reactive antibodies, but did not
induce any immune response in naïve individuals. All factors need
to be considered in the risk-based approach when designing and
planning studies for immunogenicity assessment for BTP including
multiple domain therapeutics [24]. It is critical to consider the risk
of generating an immune response, the potential severity of the
induced response and the risk/beneﬁt in the target population
[22,23].
Unfortunately, the prediction of unwanted immunogenicity of a
therapeutic product, its characteristics and clinical signiﬁcance, is
difﬁcult. As methodologies mature (in silico, in vitro and possibly
in vivo models), the ability to assess or closely predict and mitigate
immunogenicity risk for particular patient populations may be
enhanced considerably however, currently the utility of these
procedures and how they correlate clinically remains to be seen.
2. Immunogenicity assessment and clinical relevance
Currently, the most technically feasible approach for testing a
product's immunogenicity involves measuring antibodies specif-
ically generated against the product. In clinical studies, therefore,
detection and characterization of antibodies is important to un-
derstand the efﬁcacy and safety of a BTP. To date, no single assay can
provide all the necessary information on the immunogenicity
proﬁle of a biotherapeutic. Therefore, a well devised bioanalytical
strategy involving a panel of assays is required (Fig. 1). For a ma-
jority of BTPs, a typical strategy involves a screening assay for
detection based on the ability of the antibodies to bind to the
protein complemented with a conﬁrmatory step (e.g., adsorption
with excess antigen) followed by an assay for assessing the
neutralizing capacity of the antibodies. Such immunogenicity data
are generally analyzed in the context of their relevance toTable 1
Some factors which inﬂuence the unwanted immunogenicity of therapeutic proteins.
Factors determining the immunogenicity of therapeutic proteins
Product-related (Intrinsic)
 molecular structure e primary amino acid sequence or variants, novel epitopes;
 aggregates, degradation products, oxidized or deamidated forms;
 host cell DNA/proteins;
 formulation;
 primary packaging.
Product-related (Extrinsic)
 dose, route, frequency of administration, episodic/continuous treatment, duration o
 cellular or soluble target;
 biological properties of the therapeutic;
 endogenous counterpart, redundant or non-redundant.
Host-related
 genetic proﬁle;
 immune status, disease state, medication.pharmacokinetics and/or pharmacodynamics and clinical effects in
patients [2,25,26]. An understanding of the kinetics of antibody
development, whether transient or persistent, non-neutralizing or
neutralizing and how it relates to clinical impact is important. As
outlined in the WHO Guidelines on BTPs [15], a carefully selected
sampling collection plan with appropriate sampling points (base-
line, sequential sampling during treatment, wash-out/follow-up
sample) should be integrated in the strategy. For high-risk prod-
ucts, more frequent sampling and real-time testing is recom-
mended with a sampling post study in some cases (for example, for
patients that are antibody positive until they test negative in two
sequential samples). For low-risk products, retrospective moni-
toring may be considered but collection of samples at appropriate
time-points is essential. Additionally, a screening assay is pivotal in
the immunogenicity assessment of a therapeutic and should have
adequate sensitivity and must be appropriate for the intended use.
For example, since mAb therapeutics persist and have a long half-
life, the assays developed should be capable of detecting anti-
bodies in the presence of levels of the therapeutic expected to be
present in patient samples and sampling plans should include
sample collection following a wash-out period. Other confounding
factors include pre-existing cross-reactive antibodies, heterophilic
antibodies, soluble targets, or ligands, rheumatoid factors,
concomitant medication, etc. and the assessment of these incor-
porated and appropriate measures implanted to minimize any
interference.
Apart from evaluation of the presence of binding antibodies,
further characterization of positive samples in terms of titre
determination, assessment of ability to neutralize the biological
activity of the therapeutic and elucidation of the immunoglobulin
class(es) and subclass(es) may enable a better understanding of the
immunogenicity of the BTP and its clinical impact.
3. Current methods for antibody detection and
characterization
3.1. Screening assays
These determine the presence (or absence) of antibodies based
on the ability of the antibodies to recognize the relevant antigenic
determinants in the therapeutic protein. The aim of the assays is
to detect in patient samples polyclonal antibodies e these are
unique to each patient and differ in characteristics (for example,
isotype and afﬁnities etc.) between patients and also within the
same patient following multiple administrations of the product.
This scenario makes characterization of an antibody response
difﬁcult and association with clinical impact challenging. How-
ever, since these assays are the ﬁrst step in any immunogenicityf treatment, previous exposure;
Fig. 1. A simple strategy for detection of antibodies in patients receiving biotherapeutic products.
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(typically 5%) which are conﬁrmed for speciﬁcity using conﬁr-
matory assays prior to titre determination or any further
characterization.
New platforms for antibody screening are continually being
exploited to increase the ability to detect antibodies (Table 2A) but
there are numerous issues which need to be considered prior to
development of a certain assay platform. These are given below:
 selection of an appropriate assay format and design for the
therapeutic. Assay formats vary between different proteins and
likely to depend on the therapeutic protein class. For a non-
immunoglobulin recombinant protein, all platforms listed in
Table 1 are viable options for antibody determination. However,
if the protein is a mAb, the choice is limited to some extent due
to secondary antibody cross-reactivity. A direct ELISA is not
suitable unless it is modiﬁed. Although a therapeutic mAb (often
have k light chain) to capture and enzyme-labelled anti-lambda
to detect or mAb-Fab or F(ab0)2 to capture and labelled anti-IgG,
anti-IgM as detector can be used, these assays usually have a
high background due to reactivity of serum of healthy subjects
with capture reagents [27];
 assay sensitivity is dependent on the positive control used.
There are generally no reference standards or human polyclonal
antibodies available as calibrators and so assays are quasi-
quantitative. Assays are developed using a surrogate positive
control antibody, often produced by hyperimmunisation of a
non-human species or by phage display; ability of assay to detect antibodies with desired speciﬁcities
(IgM, IgG subclasses etc);
 potential interference from the therapeutic itself, particularly
with mAb therapeutics which are dosed at high levels and
persist as they have a long half-life, interference from co-
medications and/or disease-speciﬁc issues (for example, rheu-
matoid factor (RF), drug target. For minimizing therapeutic
interference, implementation of an appropriate strategy such as
acid dissociation [28,29], use of wash-out samples can be
incorporated to enable antibody detection. Likewise additional
steps will need to be introduced to address drug target inter-
ference [30].
All assays should be optimized and validated for their intended
purpose using samples froma similar patient population. Validation
of antibody assays is an essential pre-requisite for obtaining results
that are reproducible, accurate and meaningful. It is necessary to
develop validation criteria for assays in use within various labora-
tories. For screening, methods such as enzyme-linked immunosor-
bent assays (ELISAs), radio-immunoprecipitaton assays (RIPA) and
newer technologies such as electrochemiluminescence (ECL), bead-
based assay (AlphaLISA Perkin Elmer), Gyrolab system (Gyros AB),
surface plasmon resonance (SPR, Biacore), bio layer interferometry
(Octet, ForteBIo) can be used (Table 2A). Although most have mod-
erate throughput and are automated, in most clinical immunology
laboratories, ELISAs are a popular choice due to their robustness,
reliability, sensitivity, ease of automation and the requirement of a
generic platformwhich is readily available.When applied to clinical
Table 2A
Commonly used screening assays.
Type of Assay Advantages Disadvantages
Direct/Indirect ELISA Easy to use and automate
High through-put
High therapeutic tolerance
Inexpensive
Generic reagents and instrument
May bind non-speciﬁcally
High background
May fail to detect low-afﬁnity antibodies
Requires species speciﬁc secondary reagent
Bridging ELISA Easy to use and automate
High through-put
Low background, High therapeutic
tolerance in solution phase
High speciﬁcity (dual-arm binding)
Generic reagents and instrument
Antigen labelling required
May fail to detect low-afﬁnity antibodies
Highly susceptible to interference by therapeutic,
serum components e.g., anti-human Ig molecules,
multivalent targets
May not detect IgG4
Electrochemiluminescence High through-put, large dynamic range
Minimally affected by matrix
High tolerance to therapeutic in
solution phase
Detection signal consistent during life
of TAG conjugate
May require two antigen conjugates
Antigen labelling required
Susceptible to interference by therapeutic, serum
components e.g., anti-human Ig molecules, multivalent targets
May not detect IgG4
Vendor-speciﬁc equipment & reagents
Radioimmunoprecipitation assay Moderate through-put
High sensitivity
Can be speciﬁc
Inexpensive
Can be isotype speciﬁc
May not detect low-afﬁnity antibodies.
Requires radiolabelled antigen. Decay of radio-label may
affect antigen stability
Surface plasmon resonance Automated
Determines speciﬁcity, isotype, relative
binding afﬁnity
Enables detection of both ‘low-afﬁnity’
and high afﬁnity antibodies.
Detection reagent not required
Antigen immobilization may alter therapeutic. Regeneration
step may degrade antigen.
Sensitivity often less than binding assay.
Expensive vendor-speciﬁc equipment & reagents
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effects and interference due to various substances including
RF, complement and circulating therapeutic. However, theymaynot
detect low afﬁnity (for example, IgM) or rapidly dissociating anti-
bodies which, in some instances, may be neutralizing due
to thewash steps included in theprocedure. Replacementof enzyme
conjugate with a ﬂuorescent conjugate, such as euro-
piumestreptavidin, provides the basis for assays, which require a
ﬂuorimeter but may exhibit greater speciﬁcity than ‘traditional’
ELISA. Other readout methods, for example, the electro-
chemiluminescence (ECL) platform which is now gaining tremen-
dous popularity, dissociation-enhanced lanthanide ﬂuorescent
immunoassay, time-resolved ﬂuorescence resonance energy
transfer, are also available. Table 2A lists advantages and limitations
of commonly used assay methods which are brieﬂy described here.
i. ELISAse Different assay formats for example, direct, indirect,
bridging or competitive ELISA can be employed. In the direct
assay, serum or plasma samples are incubated with the
immobilized antigen and the bound antibody detected using
an enzyme-labelled anti-immunoglobulin reagent of appro-
priate speciﬁcity conjugated to an enzyme (for example,
alkaline phosphatase, horseradish peroxidase), or a small
molecule, (for example, biotin), which acts to amplify the
signal following binding of an enzyme conjugate, (for
example, streptavidinealkaline phosphatase). The ﬁnal
colour due to enzyme substrate addition is directly propor-
tional to the antibody concentration in test samples and is
measured spectrophotometrically. ELISAs rely on antigen
immobilization on a plastic surface but immobilization can
alter the antigen conformation and mask epitopes such that
antibodies speciﬁc to the masked epitopes may not be
recognized [31]. To overcome this problem, an indirect
format in which a capturing agent (for example, a mono-
clonal antibody speciﬁc to the antigen or streptavidin to
capture antigen conjugated to biotin) is immobilized toanchor the antigen allowing exposure of all available epi-
topes as in the case of IFN-b can be used [31]. These assays
require species speciﬁc secondary antibodies for detection
and this poses a problem when using an animal serum, as a
positive antibody control when evaluating human sera for
the presence of antibodies in the assay. The issue of species
speciﬁc secondary antibody is overcome in a bridging assay
and this along with other advantages means that bridging
assays are a preferential choice and are widely used by in-
dustry as opposed to direct or indirect ELISA formats.
ii. The bridging ELISA uses the antigen both for capturing the
antibody and for detection. The antigen is appropriately
conjugated or tagged such that a colorimetric signal is
developed. Sensitivity can be enhanced by using
streptavidin-coated plates to capture biotinylated antigen
and a differently labelled (for example, Digioxigenin) antigen
to complete the bridge followed by addition of enzyme-
labelled antidigoxigenin antibodies for the colorimetric
readout as shown for Erythropoietin antibodies [32]. Such
assays are claimed to have high speciﬁcity (dual arm bind-
ing), an acceptable sensitivity, are highly tolerant to the
presence of therapeutic and do not require species-speciﬁc
reagents. The disadvantage is that they may fail to detect
low afﬁnity or functionally monovalent antibodies such as
IgG4 and are susceptible to interference from serum factors
including drug target and RF. Nevertheless, these assays are
in use for detecting antibodies directed against monoclonal
antibody therapeutics and showed superiority over other
platforms in detecting antibodies when combined with acid-
dissociation procedures to dissociate immune-complexes
[33]. This approach also utilizes generic reagents and
instrumentation and removes heavy reliance on specialized
equipment from a single vendor [33].
iii. ECL e The ECL platform (MSD) employs a ruthenium-
conjugated protein instead of the enzyme conjugate.
Ruthenium labels are stable, non-radioactive and offer a
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tionereduction reaction of ruthenium ions in the presence of
tripropylamine generates an ECL reaction under appropriate
voltage stimulation. As ruthenium ions are recycled, the
electrochemical signal is ampliﬁed to yield increased sensi-
tivity. Since the ECL instrument (MSD) uses carbon electrode
plates, available as standard, high bind or precoated with
streptavidin or avidin, ECL based assays may be developed in
either conventional formats or bridging assay protocols as
used for ELISAs. This platform offers distinct attributes e a
greater dynamic assay range, high tolerance to matrix and
circulating antigen [34] and in certain instances may allow
detection of low afﬁnity antibodies depending on the format
used (solid-phase/solution phase). However, this may need
to be evaluated on a case by case basis if wash steps are
included in the procedure. Although this platform is widely
used for detecting antibodies directed against monoclonal
antibody therapeutics, it suffers from the same limitations as
the bridging ELISA andmay not detect the IgG4 isotype and is
susceptible to RF interference [35]. It is critical that conju-
gated antibody reagents, particularly the detection reagent
for ELISA or ECL bridging assays should be carefully moni-
tored for stability and aggregation to maintain the quality
and robustness of assay performance over time [35].
iv. Bead-based assay: A no-wash alternative to the ELISA is a
simple bead-based approach, offered by AlphaLISA (Perkin
Elmer) which relies on chemiluminescence and can be set up
either as sandwich or competition assays. In the former, the
analyte is captured by a biotinylated antibody bound to
streptavidin-coated donor beads and a second antibody
conjugated to AlphaLISA acceptor beads. Binding of the two
antibodies to the analyte brings the beads into proximity.
Laser irradiation of donor beads triggers a cascade of
chemical events resulting in a chemiluminescent signal. In
the competitive format, a biotinylated analyte bound to
streptavidin donor beads is used with an antibody conju-
gated to the acceptor beads. These assays exhibit remarkable
sensitivity, have a wide dynamic range and are suitable for
miniaturization and automation.
v. Surface Plasmon Resonance (SPR): These assays measure
antigeneantibody interaction in ‘real-time’ and provide a
continuous signal of the events when the sample ﬂows over
an antigen immobilised sensor chip and generates a signal
due to a change in the refractive index caused by a difference
in mass as the analyte binds to the ligand. This change in
refractive index is directly proportional to the amount (mass)
of binding antibody in the sample being tested [36].
Sequential injection of a species-speciﬁc antibody can be
used to conﬁrm speciﬁcity and to enhance signal. Generally,
SPR assays are low throughput and less sensitive compared
with ELISAs, however, they have an advantage as they are
likely to detect early immune responses characterized by low
afﬁnity antibodies, which may be neutralizing and clinically
signiﬁcant and are not detected by other assays [37,38].
Lofgren and coworkers [38] showed that the SPR despite its
low tolerance to a therapeuticwasmore effective in detecting
low afﬁnity antibodies against a therapeutic mAb than an
ELISA that incorporated an acid dissociation step to reduce
interference from themAb [38]. The ELISAwasmore sensitive
for detecting high afﬁnity antibodies and had a high tolerance
to the mAb relative to SPR [38]. In addition, since SPR can be
used for isotyping and kinetics, it is more suited for antibody
characterization. Until now, the Biacore technology (Biacore
TM, GE Healthcare) has predominantly been used for anti-
body detection by SPR but other instruments (for example,ProteOn XPR36, Bio-Rad Laboratories) are available and may
even offer advantages over existing technology.
vi. Biolayer interferometry: Another technology which is in use
for immunogenicity applications is based on the principle of
biolayer interferometry (Octet, ForteBio). Like SPR, it offers
label-free quantitation and kinetic analysis of antibodies in
real time and detects low afﬁnity antibodies. From limited
application to date, it appears that it also has a higher
tolerance to the residual therapeutic in the sample in
comparison with the ECLA and a step-wise bridging ELISA
[39].
vii. Radioimmunoprecipitation assays (RIPA): These assays are
highly sensitive but the requirement of a radiolabel and the
low throughput limits the utility of these assays in a clinical
setting. In these assays, serum is incubated with a radio-
labelled antigen and the resulting antigeneantibody com-
plex precipitated using polyethylene glycol or immobilized
protein A/G or antiglobulin and the precipitated radioactivity
assessed. This technique is used for EPO antibodies [7,40].
More recently for antibodies directed against adalimumab,
an antigen-binding assay based on protein A/G to capture Ab
& labelled mAb-Fab or F(ab0)2 to detect has been used. RIPAs
may not detect certain antibody isotypes (for example, IgM)
but detect IgG4 antibodies and low-afﬁnity antibodies which
can, in some cases, be clinically signiﬁcant [12,27,41].3.1.1. Interpretation of results
The importance of the appropriate interpretation of immuno-
genicity data in the context of regulatory oversight of these prod-
ucts is explained in the WHO Guidelines on BTP and SBP [15,16]. In
addition to the pre-licensure evaluation of BTP and SBP, it is also
important to address a need for post-marketing surveillance.
Several considerations that regulators need to apply are summa-
rized below as starting points for reviewing the immunogenicity
data.
Prior to evaluation of samples in antibody assays, it is necessary
to clearly deﬁne the criteria for interpretation of results for example,
antibody-positive or antibody-negative. The approach commonly
adopted by industry uses a ‘cut-point’ (threshold) strategy. Rec-
ommended procedures for determination of cut-points are
described in several publications [25,42]. Simplistically, samples
that generate signals belowa cut-point are considered negative and
those that are at or above the cut-point value are positive. Often the
screening cut-point is determined statistically from the level of
binding seen with the use of negative controls (~50 therapeutic-
naïve normal human serum samples; 3e4 assay runs) during assay
validation and is based upon a targeted false positive rate of 5%. So,
the cut-point ¼ mean (negative controls) þ 1.645 SD (negative
controls). In some cases, there may be outliers (due to assay back-
ground and matrix effects or due to pre-existing anti-therapeutic
antibody) which are excluded. If there is variability between runs,
alternative approaches for example, a ﬂoating cut-point which re-
quires a correction factor can be used. This situation is likely to occur
due to differences in the biology of the samples of healthy subjects
as opposed to the disease population [42].
3.1.2. Conﬁrmatory assays
These are necessary for elimination of false positive samples
identiﬁed during the initial screen using any of the procedures
stated above. A commonly adopted approach is to add excess an-
tigen to the sample and test both the treated and untreated sample
in the same assay; signal reduction in the treated versus the un-
treated sample conﬁrms the presence of antibody in the sample
[25,42]. Therefore, a conﬁrmatory assay rules out the false positive
Table 2B
Methods for detection of neutralizing antibodies.
Type of assay Advantages Disadvantages
Bioassay Functional assay which distinguishes
antibodies with neutralizing potential
Assesses neutralization capacity
May correlate with clinical response
Relatively time-consuming
Often variable e affected by serum (matrix)
effects and interfering factors e.g., inhibitors,
soluble receptors etc.
Susceptible to interference by therapeutic
Validation difﬁcult e.g., cell-lines, reagents etc.
Competitive ligand binding assay Rapid; sensitive
Relatively easy to use
Not affected by matrix
Does not require cell-lines
Easy to develop and validate
Antigen labelling may alter/denature antigen
Susceptible to interference by therapeutic
May not represent true functional read-out
May not correlate with clinical response
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The conﬁrmatory cut-point has been deﬁned as the level of signal
inhibition at or above which a sample is judged to have speciﬁc
antibody and is statistically determined by testing negative controls
(for example, drug-naïve samples) in the absence and presence of
therapeutic. Conﬁrmatory cut-point ¼ mean inhibition þ3.09 SD;
wheremean inhibition is mean percent change of negative controls
spiked with the excess of a therapeutic before assay, from an
unspiked sample (inhibition). Alternatively, protein A or G can be
used to capture all immunoglobulin from a sample followed by re-
testing of the sample, which should be negative if an antibody in
the original sample caused the positive signal.
3.1.3. Neutralizing antibody (Nab) assays
Determination of the neutralizing potential of the induced an-
tibodies is an essential element of immunogenicity evaluation.
Neutralizing antibodies inhibit the biological activity of a thera-
peutic by binding to epitope(s) within the active site(s) of the
molecule. Because Nabs can trigger clinical effects, speciﬁc and
sensitive in vitro methods are needed for detection. Two types of
Nab assays are mainly used; a cell-based bioassay or a non-cell-
based competitive ligand binding (CLB) assay (Table 2B). The
former assesses some functional aspects of the protein or mecha-
nism of action but since these assays are time-consuming, variable,
difﬁcult to establish and validate, the use of a non-cell-based CLB
assay is gaining momentum at least for some therapeutics
depending on the mechanism of action.
Understanding the mode of action, the target and effector
pathways of the therapeutic are critical for identiﬁcation of a
suitable Nab assay. Additionally, the risk of developing Nabs and the
impact on clinical sequelae also needs to be considered. For a high
risk product with an endogenous counterpart, a cell-based assay
which is sensitive and has the capability of determining Nabswith a
high speciﬁcity is required. While cell-based assays are often
employed for agonistic therapeutics, CLB assays are being consid-
ered for antagonistic molecules (for example, anti-IgE) with hu-
moral targets and are allowed by some regulatory agencies.
However, for antagonists such asmonoclonal antibody therapeutics
with effector functions for clinical efﬁcacy, cell-based assays are
recommended as the mechanism of action (MoA) cannot be
adequately reﬂected in the non-cell-based CLB assay. The prefer-
ence by regulators of cell-based assays since they represent the
physiological situation often makes them a logical ﬁrst choice;
however, bioassays may not be sufﬁciently sensitive or measure
neutralization effectively. In such cases, alternative functional
methods including non-cell-based CLB assays could be explored to
assess Nab and advice sought from regulators if considering their
use for clinical studies.
In a cell-based Nab assay, the sample is preincubated with the
therapeutic and if Nabs are present, the therapeutic is unable tobind to its target resulting in an inhibition of assay response.
Various assay types can be used for cell-based Nab assays [43].
These include cell proliferation, apoptosis, phosphorylation of
intracellular substrates, chemokine/cytokine release, and gene
expression. Cell-based assays have inherent technical challenges -
are often inﬂuenced by the sample matrix and require signiﬁcant
validation. For example, the assay should differentiate the antibody
from other sample components for example, complement, coagu-
lation factors, soluble receptors, lipids, concomitant medications
and an administered product. Use of novel approaches such as
quantitative PCR assays or reporter gene assays using chemically
treated division-arrested cells can overcome some of the problems
seen with cell-based assays [44,45].
Depending on the mechanism of action of the therapeutic and
how it interacts with cells, the assay format can vary. A therapeutic
acting directly on the cells via cell surface receptors (for example,
cytokines, mAbs directed against cell surface determinants) to
induce a response requires a simple assay format. However, if the
therapeutic blocks the ligand from interacting with its receptor and
interferes with the biological activity of the ligand (for example,
mAbs against soluble factors), the format is rather complex and the
assay technically challenging. Approaches for the design, optimi-
zation and qualiﬁcation of Nab cell-based bioassays have been
published and are a useful starting point for assay development and
understanding the potential challenges that may be encountered
[46]. Validation of Nab bioassays is important [47]; validation of
some cell-based methods is published and provides useful guid-
ance [48,49]. As for screening assays, a cut-point approach can be
used to determine whether a sample is positive for neutralizing
activity.
Non-cell-based CLB Nab assays are a simple and useful platform
for Nab assessment as they do not suffer from some of the technical
limitations of cell-based assays. As for ligand binding assays, any of
the available detection systems (for example, enzymatic, radio-
chemical, ﬂuorometric, chemiluminescence, electrochemilumine
scence or SPR technology) can be used. However, CLB assays should
only be used if relevant to the MoA of the product. For example, a
CLB assay is appropriate in a scenario where a therapeutic mAb acts
by binding to a soluble ligand thereby blocking it from interacting
with its receptor thus inhibiting the biological action of the ligand.
Since the assay procedure measures binding to the target and in-
hibition of the binding activity if Nabs are present, it is reﬂective of
the therapeutic's MoA.
Two formats can be used for CLB assays. In the simple direct
assay, the therapeutic at a deﬁned concentration in a microtiter
plate (for capture) is incubated with the labelled target/ligand (the
detector) and the resulting binding generates a signal, which is
abolished if Nabs are present in the sample. Alternatively, the
ligand or the receptor can be used for capture and the labelled
therapeutic as detection reagent, however, this approach is claimed
M. Wadhwa et al. / Biologicals 43 (2015) 298e306304to be more susceptible to interference from the therapeutic. In the
complex indirect format, the ligand is immobilized and the thera-
peutic inhibits the labelled receptor from binding to the ligand so
there is very little or no signal generated. However, if Nabs are
present, these will bind to the therapeutic and prevent it from
blocking the binding of the labelled receptor to the ligand resulting
in an increased signal. A reverse format is also feasible. Based on
limited information available, CLB assays seem promising in terms
of performance and sensitivity at least for some therapeutics but
not all. Therefore, the utility of these assays in the clinical setting is
certainly a viable option [50,51].
Evidence regarding neutralizing antibodies and clinical impact
has mainly been amassed from data derived from cell-based Nab
assays. An association of neutralizing antibodies with a loss of ef-
ﬁcacy and relapse in interferon-beta treated multiple sclerosis (MS)
is well documented [4,52]. Clinical trials in MS with Natalizumab
(Tysabri) also showed that neutralizing antibodies were associated
with loss of efﬁcacy in patients [53]. Similarly, in GM-CSF treated
patients, results from neutralization assays correlated with the ef-
fect of antibodies on clinical response [54]. However, there are also
examples in which Nabs appear to have no impact on drug efﬁcacy,
pharmacodynamics or adverse events. Therefore, when interpret-
ing data from antibody assessments, it is important to ensure that
the results of Nab assays are evaluated in the context of other
clinical endpoints to determine their signiﬁcance in terms of clin-
ical outcome.
3.1.4. Comparative immunogenicity
As stated in the WHO Guidelines on SBPs [16], immunogenicity
of similar biotherapeutic products and the reference product
should be evaluated in head-to-head comparative clinical trials in
the most sensitive patient population and employ the same clinical
protocols (for example, routes of administration, treatment
schedules, sampling procedures, sampling time points including
baseline/pre-treatment sample and storage conditions) and anti-
body assays for the generation of valid comparative data. A ho-
mogeneous population for each arm of the study is important. The
amount of immunogenicity data needed is dependent on experi-
ence gained with the reference product and/or the product class.
Although data for products used chronically should usually be
collected over a 12 month period, a shorter duration may be
justiﬁed based on the immunogenicity proﬁle of the reference
product. For example, if antibody development for a reference
product occurs within six months of treatment initiation, collection
of immunogenicity data for less than one year pre-licensing may be
justiﬁed with submission of data for the additional time-period (up
to one year) post licensure. It should be noted that antibody assays
should be conducted using the product given to the patients and
data reporting should include antibody incidence, kinetics and
onset of response, transient or persistent, relative titers and char-
acteristics of the induced antibodies. Levels of a therapeutic in the
samples should also be determined. Following this, a meaningful
evaluation of antibody data with clinical data (PK, PD, other end-
points) is needed to determine the signiﬁcance of antibodies in
terms of clinical outcome [16,17]. If signiﬁcant differences in an
immunogenicity proﬁle of the two compared products are detec-
ted, it can be concluded that the products are signiﬁcantly different.
While a lower immunogenicity of the biosimilar as opposed to the
reference product does not preclude approval as a biosimilar, all
data needs to be examined in the context of totality of evidence
available for the biosimilar product. Reduced development of
neutralizing antibodies in the case of a biosimilar may erroneously
suggest that the biosimilar is more efﬁcacious than the reference
product. In such a situation, further subgroup analysis of patients,
both antibody positive and antibody negative for the two productsmay be helpful to establish that the efﬁcacy of the two products is
similar [18]. It should be noted that comparison of immunogenicity
data of the biosimilar with historical data of the reference product
obtained in clinical trials in other studies is invalid.
4. Conclusions
A systematic evaluation of immunogenicity is necessary for
approval of all BTPs and biosimilar medicines. Assessment of
immunogenicity should be included in post-marketing monitoring
and considered in risk management and riskmitigation plans for all
products. With such safeguards and pharmacovigilance in place,
the risk of immunogenicity of a biotherapeutic should be mini-
mized resulting in better and safer products.
The importance of having a good understanding of immuno-
genicity as an important characteristic of biotherapeutic products is
an essential requirement for reviewing the data generated for
product approval. In reality, a speciﬁc problem encountered by
regulators globally is limited information that they have when they
are reviewing manufacturers' dossiers some practical consider-
ations for using immunogenicity assays for evaluation of mono-
clonal antibodies and interpretation of results were discussed in
WHO workshop held in Seoul 2014 and the case studies from that
workshop are available [55]. Immunogenicity assays are part of
product development and the expertise and experience with assay
selection, assay execution and interpretation of results of particular
assays are best understood by the developers of these assays.
Although there are well resourced regulatory agencies with
appropriate specialists for immunogenicity assessment of BTPs, in
many countries this assessment is creating a problem when it
comes to the regulatory decision making process. Sometimes, it is
also a missed opportunity for regulators to address a need for post-
marketing surveillancewith a speciﬁc focus on the immunogenicity
aspects of a product. Therefore, this article is intended as a ﬁrst step
in bringing the complex issue of immunogenicity of biotherapeutic
products including biosimilars for the attention of regulators who
are in charge of regulatory oversight of products of great impor-
tance for global public health.
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